A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood
Top Cited Papers
- 5 April 2007
- journal article
- research article
- Published by Springer Nature in Nature Protocols
- Vol. 2 (4) , 805-810
- https://doi.org/10.1038/nprot.2007.111
Abstract
Blood circulating endothelial cells (CECs) and circulating hematopoietic progenitor cells (CPCs) represent two cell populations that are thought to play important roles in tissue vascularization. CECs and CPCs are currently studied as surrogate markers in patients for more than a dozen pathologies, including heart disease and cancer. However, data interpretation has often been difficult because of multiple definitions, methods and protocols used to evaluate and count these cells by different laboratories. Here, we propose a cytometry protocol for phenotypic identification and enumeration of CECs and CPCs in human blood using four surface markers: CD31, CD34, CD133 and CD45. This method allows further phenotypic analyses to explore the biology of these cells. In addition, it offers a platform for longitudinal studies of these cells in patients with different pathologies. The protocol is relatively simple, inexpensive and can be adapted for multiple flow cytometer types or software. The procedure should take 2–2.5 h, and is expected to detect 0.1–6.0% viable CECs and 0.01–0.20% CPCs within blood mononuclear cell population.Keywords
This publication has 13 references indexed in Scilit:
- In ReplyJournal of Clinical Oncology, 2007
- Detection of Circulating Endothelial Cells: CD146-Based Magnetic Separation Enrichment or Flow Cytometric Assay?Journal of Clinical Oncology, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- The multifaceted circulating endothelial cell in cancer: towards marker and target identificationNature Reviews Cancer, 2006
- Novel Prognostic Immunohistochemical Biomarker Panel for Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2006
- Differential CD146 Expression on Circulating Versus Tissue Endothelial Cells in Rectal Cancer Patients: Implications for Circulating Endothelial and Progenitor Cells As Biomarkers for Antiangiogenic TherapyJournal of Clinical Oncology, 2006
- Lessons from phase III clinical trials on anti-VEGF therapy for cancerNature Clinical Practice Oncology, 2006
- Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer PatientsJournal of Clinical Oncology, 2005
- Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerNature Medicine, 2004
- Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cellsNature Medicine, 2003